Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Study Details
Study Description
Brief Summary
Primary Objectives
- To determine the safety and maximum tolerated dose (MTD) of Adenovirus-CD154 (Ad-ISF35) when it is injected directly into the lymph nodes of patients with CLL or SLL.
Secondary Objectives
-
To determine and monitor clinical and biological responses in patients treated with injections of Ad-ISF35.
-
To determine how ISF35 works in CLL/SLL patients' cells.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Outcome Measures
Primary Outcome Measures
- Determine the safety and maximum tolerated dose (MTD) of Adenovirus-CD154 (Ad-ISF35) when injected directly into lymph nodes of patients with CLL/SLL. [2 years]
Secondary Outcome Measures
- Determine and monitor clinical and biological responses in patients treated with intranodal injections of Ad-ISF35. [2 years]
- Determine pharmacodynamic (PD) parameters in patients treated with intranodal injections of ISF35. [2 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Diagnosis of B-cell CLL/SLL including
-
Lymphocytosis of monoclonal B-cells co-expressing ≥ one B-cell marker (CD19, CD20, or CD23) and CD5 in peripheral blood or lymph node AND
-
Bone marrow with ≥ 30% mononuclear cells having the CLL/SLL phenotype.
-
Presence of at least ONE single accessible AND palpable lymph node in the cervical, supraclavicular, axillary, or inguinal regions. The size of the lymph nodes must be larger than 2x2 cm in the horizontal and perpendicular axes.
-
Intermediate or High risk, poor prognosis CLL/SLL
-
Indication for treatment as defined by the NCI Working Group Guidelines:
-
Massive (i.e. > 6 cm below the left costal margin) or progressive splenomegaly OR
-
Massive lymph nodes or nodal clusters (i.e. > 10 cm in longest diameter), or progressive lymphadenopathy OR
-
Grade 2 or 3 fatigue OR
-
Fever ≥ 100.5˚F or night sweats for greater than 2 weeks without documented infection OR
-
Presence of weight loss ≥ 10% over the preceding 6 months OR
-
Progressive lymphocytosis with an increase of ≥ 50% over a 2-month period or an anticipated doubling time of less than 6 months.
-
Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and / or thrombocytopenia.
-
Autoimmune anemia and / or thrombocytopenia poorly responsive to corticosteroid therapy.
-
Males and females 18 years of age and older
-
Laboratory parameters as specified below:
-
Hematologic: Hemoglobin ≥ 10 g/dL (may be post-transfusion); platelet count ≥ 50 x103/mm3
-
Hepatic: Total Bilirubin < 2 X ULN, and ALT and AST < 2 x ULN
-
Renal: Creatinine ≤ 2 X ULN
-
ECOG Performance Status ≤ 2
-
Anticipated survival of at least 3 months
-
For men and women of child-producing potential, use of effective barrier contraceptive methods during the study and for one month following treatment.
-
Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
-
Negative test results for current/active infection with HIV-1, HIV-2, HTLV-1, HTLV-2, hepatitis A, B, C within 30 days of registration. (Antibody, antigen and nucleic acid tests acceptable, depending on institutional standards.).
Exclusion Criteria:
-
Pregnant or nursing women
-
Treatment with chemotherapy or monoclonal antibody within 28 days prior to entering the study.
-
Treatment with chemotherapy or monoclonal antibody during the time of participation in this trial.
-
Grade 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
-
Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, COPD)
-
Participation in any investigational drug study within 28 days prior to ISF35 administration. (Patient must have recovered from all acute effects of previously administered investigational agents)
-
History of malignancy other than CLL within five years of registration, except patients with adequately treated basal, squamous cell carcinoma or localized cervical cancer.
-
Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis.
-
Any illness or condition that in the opinion of the Investigator may affect safety of treatment or evaluation of any the study's endpoints.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of California, San Diego Moores Cancer Center | La Jolla | California | United States | 92093 |
Sponsors and Collaborators
- University of California, San Diego
- Memgen, LLC
Investigators
- Principal Investigator: Januario Castro, M.D., Assistant Clinical Professor in the Blood and Marrow Transplantation Division
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UCSD-060201
- NCT00783874